**Pending CCG approval**

NHS
Pan Mersey
Area Prescribing Committee

# SODIUM ZIRCONIUM CYCLOSILICATE powder for oral suspension (Lokelma® ▼) for treating hyperkalaemia

**The Pan Mersey Area Prescribing Committee recommends the prescribing of SODIUM ZIRCONIUM CYCLOSILICATE powder for oral suspension (Lokelma® ▼) for the treatment of hyperkalaemia, within secondary care only, in line with NICE TA599.**

**RED**

Sodium zirconium cyclosilicate powder for oral suspension (Lokelma® ▼) is licensed for the treatment of hyperkalaemia in adult patients.[1]

Patients being treated for acute hyperkalaemia must be treated in secondary care alongside other standard management.

NICE technology appraisal (TA599)[2] recommends Sodium zirconium cyclosilicate (Lokelma® ▼) as an option for treating hyperkalaemia in adults only if used:

- in emergency care for acute life-threatening hyperkalaemia alongside standard care **or**
- in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they:
    - have a confirmed serum potassium level of at least 6.0 mmol/litre
    - are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia **and**
    - are not on dialysis.

In outpatient care, stop sodium zirconium cyclosilicate if RAAS inhibitors are no longer suitable.

Sodium zirconium cyclosilicate is recommended **only** if the company provides it according to the commercial arrangement. This PAS scheme discounted price is only available to secondary care providers, therefore all prescribing should be retained by secondary care. Monitoring of the patient's renal profile must also be carried out by the secondary care specialist, and it is not expected that primary care will be asked to do this.

Any specialist starting sodium zirconium cyclosilicate must write to the patient's GP to inform them that it is being prescribed within secondary care so that this can be recorded on the primary care clinical system.

An accompanying NICE Resource Impact Report is available. Sodium zirconium cyclosilicate is not PBR excluded.

**References**


1. AstraZeneca UK Limited. Summary of Product Characteristics: Lokelma 10g powder for suspension, 30 August 2019. Accessed 11 September 2019.
2. National Institute for Health and Care Excellence. Technology Appraisal 599: Sodium zirconium cyclosilicate for treating hyperkalaemia, 04 September 2019. Accessed 11 September 2019.


**Note**: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.